226 related articles for article (PubMed ID: 36216147)
1. CD55 in cancer: Complementing functions in a non-canonical manner.
Bharti R; Dey G; Lin F; Lathia J; Reizes O
Cancer Lett; 2022 Dec; 551():215935. PubMed ID: 36216147
[TBL] [Abstract][Full Text] [Related]
2. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
3. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.
Mikesch JH; Schier K; Roetger A; Simon R; Buerger H; Brandt B
Cell Oncol; 2006; 28(5-6):223-32. PubMed ID: 17167176
[TBL] [Abstract][Full Text] [Related]
4. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.
Pritchard MT; McMullen MR; Stavitsky AB; Cohen JI; Lin F; Edward Medof M; Nagy LE
Gastroenterology; 2007 Mar; 132(3):1117-1126. PubMed ID: 17383432
[TBL] [Abstract][Full Text] [Related]
5. Complement decay accelerating factor (DAF)/CD55 in cancer.
Spendlove I; Ramage JM; Bradley R; Harris C; Durrant LG
Cancer Immunol Immunother; 2006 Aug; 55(8):987-95. PubMed ID: 16485129
[TBL] [Abstract][Full Text] [Related]
6. Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.
Wang Y; Li Y; Dalle Lucca SL; Simovic M; Tsokos GC; Dalle Lucca JJ
J Neuroinflammation; 2010 Apr; 7():24. PubMed ID: 20380727
[TBL] [Abstract][Full Text] [Related]
7. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.
Saygin C; Wiechert A; Rao VS; Alluri R; Connor E; Thiagarajan PS; Hale JS; Li Y; Chumakova A; Jarrar A; Parker Y; Lindner DJ; Nagaraj AB; Kim JJ; DiFeo A; Abdul-Karim FW; Michener C; Rose PG; DeBernardo R; Mahdi H; McCrae KR; Lin F; Lathia JD; Reizes O
J Exp Med; 2017 Sep; 214(9):2715-2732. PubMed ID: 28838952
[TBL] [Abstract][Full Text] [Related]
8. Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55).
Kim Y; Lee YW; Kim H; Chung DK
Toxins (Basel); 2019 Apr; 11(5):. PubMed ID: 31027358
[TBL] [Abstract][Full Text] [Related]
9. Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Kwon YC; Kim H; Meyer K; Di Bisceglie AM; Ray R
J Immunol; 2016 Aug; 197(4):1127-36. PubMed ID: 27357152
[TBL] [Abstract][Full Text] [Related]
10. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
11. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
[TBL] [Abstract][Full Text] [Related]
12. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
13. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
15. Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure.
Narayanan GA; Murray IA; Krishnegowda G; Amin S; Perdew GH
J Pharmacol Exp Ther; 2012 Aug; 342(2):345-55. PubMed ID: 22553215
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D3 promotes a sustained LPS-induced NF-κB-dependent expression of CD55 in human monocytic THP-1 cells.
Izban MG; Nowicki BJ; Nowicki S
PLoS One; 2012; 7(11):e49318. PubMed ID: 23152895
[TBL] [Abstract][Full Text] [Related]
17. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer.
Holla VR; Wang D; Brown JR; Mann JR; Katkuri S; DuBois RN
J Biol Chem; 2005 Jan; 280(1):476-83. PubMed ID: 15520008
[TBL] [Abstract][Full Text] [Related]
19. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1992 Nov; 66(5):810-4. PubMed ID: 1384641
[TBL] [Abstract][Full Text] [Related]
20. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
